Polyrizon Ltd. (PLRZ) Stock Price, Quote & News

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorp...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 374 0120

Website: www.polyrizon-biotech.com

Address:

5 Ha-Tidhar Street, Ra'anana, Israel

PTY_KC Dec. 5 at 7:18 PM

$PLRZ don’t be surprised if we close at $15. Just saying 😃😃😃

0 · Reply

JimmyCashMoney Dec. 5 at 7:13 PM

$PLRZ shorts are going to need to cover their position soon before the next face rip comes

0 · Reply

Kenmore12 Dec. 5 at 7:11 PM

$PLRZ technical bounce. They will short it at 14.25

0 · Reply

JimmyCashMoney Dec. 5 at 7:03 PM

$PLRZ

0 · Reply

Bazzzigar Dec. 5 at 6:57 PM

$PLRZ

0 · Reply

SteveStachion Dec. 5 at 6:56 PM

$PLRZ push push push

0 · Reply

TheMoonWatchers Dec. 5 at 6:39 PM

That call was insane dude, Made my whole week! Made 7k$ profit :) Shout out to @ReversalFox for nailing that run last night! FOLLOW him, Amazing trader! Adding $SMX $CAPR $PLRZ $GURE now

0 · Reply

JimmyCashMoney Dec. 5 at 6:26 PM

$PLRZ he means Monday and $19 which ever comes first

0 · Reply

GABBYGIRL Dec. 5 at 6:25 PM

$PLRZ Monday or $9.00, whichever comes 1st is time to enter

0 · Reply

F74 Dec. 5 at 6:23 PM

$PLRZ la sec è un'ente inutile se non dannoso ! permettere queste due giornate è pazzesco ! azionisti massacrati! una vergogna assurda

0 · Reply

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 3, 2025, 9:28 AM EST - 2 days ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 2, 2025, 7:55 AM EST - 3 days ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Nov 6, 2025, 8:55 AM EST - 4 weeks ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Oct 6, 2025, 8:21 AM EDT - 2 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Sep 19, 2025, 8:15 AM EDT - 2 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 12, 2025, 7:26 AM EDT - 3 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Aug 14, 2025, 8:14 AM EDT - 4 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Jul 15, 2025, 7:55 AM EDT - 5 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jun 12, 2025, 7:32 AM EDT - 6 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

May 23, 2025, 4:15 PM EDT - 6 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 21, 2025, 7:10 AM EDT - 7 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 13, 2025, 7:45 AM EDT - 7 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Apr 25, 2025, 7:37 AM EDT - 8 months ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 11, 2025, 4:15 PM EDT - 8 months ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 2, 2025, 9:05 AM EDT - 8 months ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 1, 2025, 4:09 PM EDT - 8 months ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 8 months ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 27, 2025, 8:25 AM EDT - 9 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 25, 2025, 4:04 PM EDT - 9 months ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 14, 2025, 8:35 AM EDT - 9 months ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 13, 2025, 7:51 AM EDT - 9 months ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 11, 2025, 4:27 PM EDT - 9 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 10, 2025, 7:47 AM EDT - 9 months ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Jan 30, 2025, 5:55 AM EST - 11 months ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 23, 2025, 6:40 AM EST - 11 months ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 19, 2024, 7:22 AM EST - 1 year ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 18, 2024, 6:25 AM EST - 1 year ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 13, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 2, 2024, 8:02 AM EST - 1 year ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Oct 30, 2024, 1:50 PM EDT - 1 year ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Oct 30, 2024, 10:28 AM EDT - 1 year ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Oct 28, 2024, 7:02 PM EDT - 1 year ago

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

PTY_KC Dec. 5 at 7:18 PM

$PLRZ don’t be surprised if we close at $15. Just saying 😃😃😃

0 · Reply

JimmyCashMoney Dec. 5 at 7:13 PM

$PLRZ shorts are going to need to cover their position soon before the next face rip comes

0 · Reply

Kenmore12 Dec. 5 at 7:11 PM

$PLRZ technical bounce. They will short it at 14.25

0 · Reply

JimmyCashMoney Dec. 5 at 7:03 PM

$PLRZ

0 · Reply

Bazzzigar Dec. 5 at 6:57 PM

$PLRZ

0 · Reply

SteveStachion Dec. 5 at 6:56 PM

$PLRZ push push push

0 · Reply

TheMoonWatchers Dec. 5 at 6:39 PM

That call was insane dude, Made my whole week! Made 7k$ profit :) Shout out to @ReversalFox for nailing that run last night! FOLLOW him, Amazing trader! Adding $SMX $CAPR $PLRZ $GURE now

0 · Reply

JimmyCashMoney Dec. 5 at 6:26 PM

$PLRZ he means Monday and $19 which ever comes first

0 · Reply

GABBYGIRL Dec. 5 at 6:25 PM

$PLRZ Monday or $9.00, whichever comes 1st is time to enter

0 · Reply

F74 Dec. 5 at 6:23 PM

$PLRZ la sec è un'ente inutile se non dannoso ! permettere queste due giornate è pazzesco ! azionisti massacrati! una vergogna assurda

0 · Reply

harryjerry Dec. 5 at 6:16 PM

$PLRZ $COST $TE $SPY Bullish forces have taken absolute dominance. The stock is currently experiencing unprecedented trading volume, signaling strong momentum and the potential for a major breakout. Market forecasts indicate that the stock is expected to rise by 100% by 2026, further increasing its market capitalization, which would be a highly attractive opportunity for investors seeking high-growth prospects.

0 · Reply

SonicPricers Dec. 5 at 6:15 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $GRAB $PLRZ $DXYZ $HPE Hopeful

0 · Reply

cmmnshrs_RKng Dec. 5 at 6:12 PM

$PLRZ "Delivery of the securities is expected to be made on or about December 5, 2025 subject to customary closing conditions"

0 · Reply

hobartchilde Dec. 5 at 6:08 PM

$QCLS $TE $PLRZ $HRL Bullish forces have taken absolute dominance. The stock is currently experiencing unprecedented trading volume, signaling strong momentum and the potential for a major breakout. Market forecasts indicate that the stock is expected to rise by 100% by 2026, further increasing its market capitalization, which would be a highly attractive opportunity for investors seeking high-growth prospects.

0 · Reply

Stonky_Mcprofitface Dec. 5 at 6:06 PM

$PLRZ Do I have this right? The stock doubled yesterday because the nasal spray GEL formulation stuck to the nose better than the LIQUID formulation… on testing in…a rabbit?

0 · Reply

JimmyCashMoney Dec. 5 at 6:01 PM

$PLRZ

0 · Reply

Buraku Dec. 5 at 5:57 PM

$PLRZ never trust a company with a ceo that has a porn Star name

0 · Reply

JimmyCashMoney Dec. 5 at 5:56 PM

$PLRZ shares = not so many = next $SMX

0 · Reply

Buraku Dec. 5 at 5:56 PM

$PLRZ even the iron dome ain’t gonna help this POZS

0 · Reply

labububub Dec. 5 at 5:47 PM

$PLRZ go up！

0 · Reply

MICK500 Dec. 5 at 5:46 PM

$PLRZ ok ok Ill buy back in

0 · Reply

__MoonWatcher Dec. 5 at 5:45 PM

That call was insane dude, Made my whole week! Made 7k$ profit :) Shout out to @ReversalFox for nailing that run last night! FOLLOW him, Amazing trader! Still watching $PLRZ $PLTR $APLD $NVAX C

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,429,814
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A